dc.contributor.author | Maio, M | |
dc.contributor.author | Hamid, O | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Covre, A | |
dc.contributor.author | Altomonte, M | |
dc.contributor.author | Calabrò, L | |
dc.contributor.author | Vardhana, SA | |
dc.contributor.author | Robert, C | |
dc.contributor.author | Ibrahim, R | |
dc.contributor.author | Anichini, A | |
dc.contributor.author | Wolchok, JD | |
dc.contributor.author | Giacomo, AMD | |
dc.date.accessioned | 2020-10-07T11:57:09Z | |
dc.date.issued | 2020-08 | |
dc.identifier.citation | Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 26 (16), pp. 4201 - 4205 | |
dc.identifier.issn | 1078-0432 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4130 | |
dc.identifier.eissn | 1557-3265 | |
dc.identifier.doi | 10.1158/1078-0432.ccr-20-1657 | |
dc.description.abstract | The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic. | |
dc.format | Print-Electronic | |
dc.format.extent | 4201 - 4205 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Pneumonia, Viral | |
dc.subject | Coronavirus Infections | |
dc.subject | Neoplasms | |
dc.subject | Treatment Outcome | |
dc.subject | Clinical Trials as Topic | |
dc.subject | Pandemics | |
dc.subject | CTLA-4 Antigen | |
dc.subject | Programmed Cell Death 1 Receptor | |
dc.subject | Clinical Decision-Making | |
dc.subject | Betacoronavirus | |
dc.subject | Antineoplastic Agents, Immunological | |
dc.subject | B7-H1 Antigen | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.title | Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-06-09 | |
rioxxterms.versionofrecord | 10.1158/1078-0432.ccr-20-1657 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical cancer research : an official journal of the American Association for Cancer Research | |
pubs.issue | 16 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 26 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Melanoma and Kidney Cancer | en_US |
dc.contributor.icrauthor | Larkin, James | |